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β-Catenin binds to the cytoplasmic region of the type 1 membrane glycoprotein MUC1. In the current study, we utilized HEK293T cells
expressing the full-length MUC1 protein, or a CD8/MUC1 fusion protein containing only the MUC1 cytoplasmic tail, to investigate the effects of
β-catenin binding to MUC1 on downstream β-catenin-dependent events. Compared with HEK293T cells transfected with empty vector or CD8
alone, expression of the MUC1 cytoplasmic tail inhibited β-catenin binding to E-cadherin, decreased translocation of β-catenin into the nucleus,
reduced activation of the LEF-1 transcription factor, and blocked expression of the cyclin D1 and c-Myc proteins. Furthermore, expression of
MUC1 was associated with decreased cell proliferation, either in the context of the transfected HEK293T cells, or when comparing wild type
(Muc1+/+) vs. knockout (Muc1−/−) mouse primary tracheal epithelial cells. We conclude that MUC1 inhibits cell proliferation through a β-catenin/
LEF-1/cyclin D1/c-Myc pathway.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cyclin D1; c-Myc; E-cadherin; LEF-1; Cancer; Transcription; Nucleus; Cytoplasm; Membrane; Reepithelialization1. Introduction
MUC1 is a membrane-bound glycoprotein expressed by
hematopoietic and epithelial cells, and overexpressed by most
carcinomas [1,2]. MUC1 is initially synthesized as a single
polypeptide chain that is autocatalytically cleaved in its
extracellular SEA domain at a Gly–Ser peptide bond to
generate NH2- and COOH-terminal subunits, which subse-
quently reside as a heterodimer complex on the cell surface
[3–5]. The NH2-terminal subunit consists of the majority of
the protein's extracellular domain. The COOH-terminal
subunit is composed of a juxtamembrane region of the
ectodomain, a single-pass transmembrane region, and a cyto-
plasmic tail (CT) [6]. The CT is highly conserved amongAbbreviations: ALI, air–liquid interface; CT, cytoplasmic tail; GSK,
glycogen synthase kinase; LEF, lymphoid enhancer factor; TCF, T cell factor;
TCL, total cell lysate; TER, transepithelial electrical resistance; TSE, tracheal
surface epithelial
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doi:10.1016/j.bbamcr.2007.04.009different species and possesses 7 tyrosine residues as potential
phosphorylation sites. In particular, 4 tyrosines are located
within sequences that, once phosphorylated, constitute signal
transduction motifs: Y20HPM (PI3K), YPTY29 (Shc), Y46EEV
(c-Src), and Y60TNP (Grb2) [7,8]. (Amino acids are numbered
beginning with the first residue of the 72 amino acid CT) (Fig.
1). The presence of these signaling sites and absence of
tyrosine kinase autophosphorylation suggests that MUC1 is
functionally analogous to cytokine receptors [7], but the role of
MUC1 in signal transduction remains to be determined.
Previous studies have shown that MUC1 plays a role in a
diverse array of cellular processes including differentiation [9–
11], promotion or inhibition of cell–cell and cell–matrix
adhesion [12–15], mediation of pathogen–host cell interaction
[16–18], adaptive immunity [19–21], and oncogenesis [22–
25]. Some of these effects were correlated with expression and
phosphorylation of the MUC1 CT. For example, Kohlgraf et al.
[26] showed that pancreatic carcinoma cells overexpressing
full-length MUC1 exhibited an altered invasive and metastatic
phenotype compared with cells expressing a CT-truncated
Fig. 1. Schematic illustration of the MUC1 constructs used in this study. MUC1
regions are denoted by rectangles and CD8 regions by ovals. EC, extracellular
region; TM, transmembrane region; CT, cytoplasmic tail region. The amino acid
sequences of the CD8 and MUC1 TM and CT regions are indicated by the single
letter code.
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mice expressing a human MUC1 transgene and challenged with
MUC1-expressing tumor cells was significantly prolonged
following vaccination with peptides derived from the CT [27].
Schroeder et al. [28] reported that MUC1 expressed in the
transgenic mice was tyrosine phosphorylated on its CT and
associated with all 4 erbB receptors including the EGF receptor
(erbB1). Quin andMcGuckin [29] demonstrated that the highest
levels of MUC1 CT tyrosine phosphorylation occurred during
recolonization of culture dishes, or in low-density cultures of
breast and ovarian cancer cells. EGF receptor-mediated
phosphorylation of Y46 in the MUC1 CT regulated its
interaction with β-catenin [30]. Partnered with the transmem-
brane cadherin proteins, β-catenin is a submembrane compo-
nent of adherens junctions intercellular adhesion complexes,
and forms a transcriptional activator in association with the
lymphoid enhancer factor/T cell factor (LEF/TCF) family of
proteins. Several target genes of β-catenin-LEF/TCF stimulate
cell proliferation, including cyclin D1 and c-Myc [31].
Interaction of the MUC1 CT with β-catenin and the β-
catenin-like protein p120ctn promoted nuclear localization of
both transcriptional cofactors implying that overexpression of
MUC1 by cancer cells could potentially contribute to
oncogenesis by disruption of β-catenin/p120ctn function during
cell–cell interactions and/or transcriptional regulation [32,33].
Recently, we constructed a novel fusion protein containing the
extracellular and transmembrane regions of CD8 attached to theMUC1 CT (CD8/MUC1) to study downstream signaling emanat-
ing from MUC1 [8,34]. (The amino acid sequence of the trans-
membrane and CT regions of the CD8/MUC1 protein is
IVAPLAGTCGVLLLSLVITLYCNHRKDPRRKNYGQLDIFPAR-
DTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAG-
NGGSSLSYTNPAVAATSANL where the CD8 transmembrane
region is indicated in italic. The corresponding sequence of the
wild-type MUC1 protein is VPGWGIALLVLVCVLVALAIVYLIA-
LAVCQCRRKNYGQLDIFPARDTYHPMSEYPTYHTH-
GRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAATSANL
where the MUC1 transmembrane region is indicated in italic)
(Fig. 1). HEK293T cells stably expressing CD8/MUC1 were used
to identify 4 sites of CT tyrosine phosphorylation, which
corresponded to the predicted PI3K, Shc, c-Src, andGrb2 signaling
sites (Y20, Y29, Y46, and Y60). Based on prior reports that
tyrosine phosphorylation of the MUC1 CTwas involved in cell
proliferation [29], and that phosphorylation of Y46 in particular
influenced the interaction of MUC1 with β-catenin [30], we
undertook the current study to examine the relationship
between MUC1, β-catenin, and cell proliferation. We hypoth-
esized that MUC1 overexpression would shift the intracellular
pool of β-catenin out of the nucleus resulting in decreased cell
proliferation. Our results demonstrated that, compared with
MUC1-negative cells, cells expressing theMUC1 CTexhibited
decreased nuclear localization of β-catenin, reduced transacti-
vation of LEF-1, lower levels of cyclin D1 and c-Myc proteins,
and diminished cell proliferation.
2. Materials and methods
2.1. Antibodies
The sources of antibodies were as follows: CD8 (#sc-7188, Santa Cruz
Biotechnology, Santa Cruz, CA), β-catenin (#610153, BD Transduction Labs,
Lexington, KY), γ-catenin (#610253, BD Transduction Labs), cyclin D1 (#sc-
20044, Santa Cruz), c-Myc (#sc-41, Santa Cruz), lamin B1 (#sc-20682, Santa
Cruz), IκBα (#sc-7182, Santa Cruz), and horseradish peroxidase-conjugated
mouse IgG (KPL, Gaithersburg, MD). Rabbit antiserum CT33 was prepared
against a synthetic peptide corresponding to the COOH-terminal 17 amino acids
of the MUC1 CT and has been characterized [8,34,35]. Normal IgG (#N103)
was from Oncogene (Cambridge, MA).
2.2. Plasmids
The full-length MUC1, CD8/MUC1, and CD8/MUC1-ΔCT (CT-truncated)
cDNAs were cloned in the pcDNA3.1 expression plasmid (Invitrogen, Carlsbad,
CA). Their encoded proteins are schematically illustrated in Fig. 1. The LEF-1-
luciferase and β-catenin plasmids were generous gifts from Dr. Daniel Sussman
(NCI, NIH, Bethesda, MD). The phRL-TK plasmid encoding Renilla luciferase
was from Promega (Madison, WI).
2.3. Cell transfections
HEK293T cells (American Type Culture Collection, Manassas, VA) were
maintained in DMEM supplemented with 100 units/ml penicillin, 100 μg/ml
streptomycin, and 10% FBS (GIBCO BRL, Gaithersburg, MD). Preconfluent
(∼70%) cells in 100 mm dishes were transfected with 1.0 μg of the respective
plasmids using PolyFect (Qiagen, Santa Clara, CA) according to the
manufacturer's procedure. Stable cell clones were established following
transfection with plasmids encoding the pcDNA empty vector, full-length
MUC1, CD8/MUC1, or CD8/MUC1-ΔCT proteins by continuous passage in
DMEM containing 10% FBS and 800 μg/ml of G418.
Fig. 3. Coimmunoprecipitation of β-catenin with MUC1 requires the CT. (A)
Lysates of the indicated cells were immunoprecipitated with IgG or antibody to
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Cells were lysed on ice for 20 min in PBS, pH 7.2 containing 50 mM NaF,
5.0 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and 1% protease
inhibitor cocktail (10 μg/ml pepstatin, 10 μg/ml leupeptin, 1.0 μg/ml aprotinin,
and 0.1 mM EDTA) (Sigma, St. Louis, MO). Lysates were centrifuged at
14,000×g for 10 min at 4 °C and protein concentrations measured by a detergent
compatible Lowry assay [36] using bovine serum albumin as standard. Equal
protein aliquots were subjected to immunoprecipitation with 1.0 μg of normal
IgG or antibodies against CD8, MUC1, or β-catenin plus protein A agarose
beads at 4 °C for 16–24 h. Immunoprecipitated proteins were resolved by SDS-
PAGE on 8% acrylamide gels [37], electroblotted to PVDF membrane at 100 V
for 1 h in 20 mM Tris–HCl, pH 8.3, 0.19 M glycine, 20% methanol, and reacted
with primary antibodies (1/1,000) at 4 °C for 16–24 h. Following incubation, the
membranes were reacted with horseradish peroxidase-conjugated secondary
antibody for 1 h and developed with enhanced chemiluminescence reagents. In
some experiments, total cell lysates (TCL) constituting 1% (w/v) of each
fraction were analyzed by immunoblotting without immunoprecipitation as
negative controls for equal protein expression and as comigration markers for
the immunoprecipitated proteins.
2.5. Preparation of nuclear extracts
Nuclear extracts of pcDNA-, MUC1-, CD8/MUC1-, and CD8/MUC1-ΔCT-
HEK293T cells were prepared as described [32]. Cells in 100 mm dishes at
∼90% confluence were washed with PBS, pH 7.2 at 4 °C, scrapped from the
dishes, and centrifuged at 1000×g for 10 min at 4 °C. The cell pellet was
resuspended in 2.5 ml of PBS containing 1% Triton X-100 and 1% protease
inhibitor cocktail, incubated on ice for 10 min, and centrifuged at 2000×g. The
remaining nuclear pellet was washed 3 times with lysis buffer at 4 °C,
resuspended in 0.2 ml of PBS at 4 °C, and sonicated for 30 s on ice. DNase I
(100 units) (Promega) was added, the sonicate incubated for 45 min at 4 °C, and
sonication was repeated. The sonicate was centrifuged at 14,000×g for 10 min at
4 °C and the supernatant used as the nuclear extract. Protein levels were
quantified as above.Fig. 2. β-catenin coimmunoprecipitates with MUC1. (A) Lysates of
16HBE14o−, 1HAEo−, and BEAS-2B cells were immunoprecipitated with
normal IgG or MUC1 antibody CT33 and precipitated proteins were
immunoblotted with antibody to β-catenin. TCL, total cell lysate not subjected
to immunoprecipitation. (B) Lysates of MUC1-HEK293T cells were immuno-
precipitated with IgG or CT33 and immunoblotted with antibody to β-catenin or
γ-catenin.
CD8 followed by immunoblotting with antibody to β-catenin. (B) Immuno-
blotting of β-catenin in TCL to demonstrate equal sample loading and transblot
efficiencies. (C) Reciprocal coimmunoprecipitation analysis using lysates of
CD8/MUC1-HEK293T cells that were immunoprecipitated with IgG or
antibody to β-catenin followed by immunoblotting with antibody to CD8.2.6. LEF-1-luciferase assay
CD8/MUC1- and CD8/MUC1-ΔCT-HEK293T cells in 24 well plates at
∼70% confluence were transfected with 0.5 μg/well of a LEF-1-luciferase
plasmid or the pGL2 empty vector (Promega) plus 10 ng/well of phRL-TK
(encoding Renilla luciferase) in the presence or absence of 0.5 μg/well of the
β-catenin plasmid using 2.5 μl/well of Lipofectamine 2000 (Invitrogen)
according to the manufacturer's protocol. At 48 h post-transfection, luciferase
activity was determined using the Dual luciferase assay system (Promega).
Relative luciferase activity was calculated as the ratio of firefly to Renilla
luciferase activities.
2.7. Immunofluorescence microscopy
CD8/MUC1- and CD8/MUC1-ΔCT-HEK293T cells were cultured on 18
mm glass coverslips in 6 well plates and subjected to immunofluorescence
analysis as described [34]. Briefly, the cells were washed with cold PBS,
immediately fixed using 4% formaldehyde in PBS for 5 min, and permeabilized
with 0.1% Triton X-100 in PBS for 2 min. After fixation, the cells were
sequentially incubated for 1 h in PBS containing 0.1% Tween 20 and 3% BSA,
1 h with normal IgG or antibodies to cyclin D1 or c-Myc (0.7 μg/ml), and 1 h
with AlexaFluor 488-conjugated secondary antibody (0.7 μg/ml) with PBS/
Tween 20 washes between each step. Cells were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) in PBS. Images were photographed using a
confocal fluorescence microscope (Eclipse E800, Nikon, Melville, NY) and
processed using Nikon EZ-C1 version 2.10 software.
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CD8/MUC1- and CD8/MUC1-ΔCT-HEK293T cells were seeded in 24 well
plates at 5×104 cells/well in DMEM containing 3% or 10% FBS plus antibiotics
and incubated at 37 °C in 5% CO2. At 24, 48, 72, 96, and 120 h post-seeding,
viable cell numbers were determined using the XTTcell proliferation kit (Roche,
Indianapolis, IN) according to the manufacturer's instructions. Optical densities
at 492 nm and 630 nm were measured and corrected for background absorbance
using XTT plus culture medium alone.
2.9. Mouse primary TSE cell culture
Mouse tracheal surface epithelial (TSE) cells were harvested and cultured
by a procedure adapted from the published protocol [38,39]. Briefly, tracheas
were cannulated, removed aseptically, treated with type XIV pronase (Sigma),
and the released cells incubated in 100 mm dishes for 2 h to adhere fibroblasts.
The non-adherent cells were cultured in 12 mm Millicell plate inserts
(Millipore, Bedford, MA) coated with type IV human placenta collagen
(Sigma) at approximately 1.0×105 cells/cm2. Culture medium consisted of
DMEM/Ham's F-12 (1/1) containing 10 μg/ml insulin, 5.0 μg/ml transferrin,
25 ng/ml epidermal growth factor, 10−7 M hydrocortisone, 25 ng/ml cholera
toxin, 1% bovine pituitary extract, 1×10−8 M all-trans retinoic acid, 5% FBS,
50 units/ml penicillin, and 50 μg/ml streptomycin (Invitrogen). At 24 h post-
seeding, air–liquid interface (ALI) culture was initiated by removing the culture
medium in the upper chamber, rinsing the apical surface of the cells with PBS,
and replacing the medium only in the bottom compartment. At various time of
ALI culture, viable cell numbers were determined using the XTT assay and
transepithelial electrical resistance (TER) was measured with an epithelial
Ohm-voltmeter (Millipore).Fig. 4. Expression of MUC1 inhibits E-cadherin/β-catenin coimmunoprecipita-
tion. pcDNA-HEK293T and MUC1-HEK293T cell lysates were immunopre-
cipitated with antibody to E-cadherin followed by immunoblotting with
antibody to β-catenin (A) or γ-catenin (B). A bar graph of the results is
shown below the blots. (C) Control immunoblot analysis of E-cadherin, β-
catenin, and γ-catenin in TCLs of pcDNA- and MUC1-HEK293T cells.
Fig. 5. Expression of the MUC1 CT inhibits nuclear translocation of β-catenin.
Nuclear extracts of pcDNA-, MUC1-, CD8/MUC1-ΔCT-, and CD8/MUC1-
HEK293T cells were analyzed by immunoblotting with antibodies to β-catenin
(A) or lamin B1 (B). A bar graph of the results is shown below the blot in (A).
(C) Cytoplasmic (C) and nuclear (N) extracts were analyzed by immunoblotting
with IκBα antibody to demonstrate absence of cytoplasmic proteins in the
nuclear extracts. Each fraction was present at 1% (w/v) on the gel.2.10. Statistical analysis
Replicates of 3 samples were used for each treatment group. Mean±SD
values for each group were calculated, differences between groups were
assessed using the Students t-test, and considered significant at pb0.05. All
experiments were repeated at least 2 times.3. Results
3.1. Interaction of the MUC1 CT with β-catenin
Numerous reports have documented that MUC1 binds to β-
catenin [30,33,40–46]. However, all of these prior studies
utilized cancer cell lines, primary tumors, or purified proteins
derived from them. Since MUC1 is overexpressed and displays
aberrant structural and cellular localization properties by cancer
cells [1,2], we sought to determine if MUC1 binds to β-catenin
Fig. 6. Expression of the MUC1 CT reduces β-catenin-dependent LEF-1
activation. (A) CD8/MUC1-ΔCT- and CD8/MUC1-HEK293T cells were
cotransfected with the negative control pGL2 or LEF-1-luciferase plasmids
plus the phRL-TK (Renilla luciferase) plasmid and relative luciferase activity
(firefly/Renilla) determined at 24 h post-transfection. (B) CD8/MUC1-ΔCT-
and CD8/MUC1-HEK293T cells were cotransfected with phRL-TK and pGL2
or LEF-1-luciferase plus β-catenin, and relative luciferase activity determined at
24 h post-transfection. Each bar represents the mean±SD of triplicate cultures.
N.S., not significantly different.
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role of MUC1 in the airways, and its possible function during
reepithelialization following acute lung injury, we performed
MUC1/β-catenin coimmunoprecipitation studies using the
16HBE14o−, 1HAEo−, and BEAS-2B cells. These cells are
non-malignant, SV40 large T antigen-immortalized human
airway epithelial cell lines that maintain differentiated epithelial
morphology and functions [47–49]. As shown in Fig. 2A,
immunoprecipitation of MUC1 from cell lysates using a CT
specific antibody (CT33) followed by immunoblot analysis
using antibody to β-catenin revealed a protein band that
comigrated with β-catenin detected in total cell lysate (TCL).
No β-catenin band was detected in control immunoprecipitates
with non-immune antibodies.
MUC1/β-catenin coimmunoprecipitation was also observed
using HEK293T cells stably transfected with a full-length
MUC1 cDNA (Fig. 2B). (Non-transfected HEK293T cells do
not express MUC1 [35].) Because MUC1 was reported to
coimmunoprecipitate with γ-catenin in breast cancer cells [40],
but not pancreatic cancer cells (33), we stripped and reprobed
the membrane with antibody against γ-catenin, but failed to
detect MUC1/γ-catenin coimmunoprecipitation (Fig. 2B).
Coimmunoprecipitation of β-catenin was also seen using
HEK293T cells expressing a CD8/MUC1 fusion protein
containing only the CT of MUC1 (Fig. 3A). CD8/MUC1/β-
catenin coimmunoprecipitation was not seen using HEK293T
cells transfected with the empty pcDNA vector, or using a
protein construct deleted of the MUC1 CT and containing only
the extracellular and transmembrane domains of CD8 (CD8/
MUC1-ΔCT). All cells examined expressed β-catenin in TCL(Fig. 3B) and, as documented in our prior report [34], the
expression levels of the CD8/MUC1 and CD8/MUC1-ΔCT
proteins were equal in the transfected cells as assessed by both
immunoblot and immunofluorescence microscopy. In the
reciprocal experiment, β-catenin antibody immunoprecipitates
were analyzed for the presence of CD8/MUC1 by immuno-
blotting with CD8 antibody. The findings confirmed binding of
the MUC1 CT to β-catenin (Fig. 3C).
3.2. MUC1 competes with E-cadherin for binding to β-catenin
Catenins were initially identified by coimmunoprecipitation
with E-cadherin [50]. Therefore, we investigated whether or not
binding of β-catenin to MUC1 would interfere with its
interaction with E-cadherin. Equal protein aliquots of pcDNA-
and MUC1-HEK293T cell lysates were immunoprecipitated
with E-cadherin antibody followed by immunoblotting with β-
catenin antibody. In contrast to pcDNA-HEK293T cells, E-
cadherin/β-catenin coimmunoprecipitation was not seen in cells
expressing MUC1 (Fig. 4A). However, MUC1 expression did
not inhibit binding of γ-catenin to E-cadherin (Fig. 4B), in
concert with the results in Fig. 2B indicating that MUC1 did not
interact with γ-catenin.
3.3. The MUC1 CT inhibits nuclear localization of β-catenin
β-Catenin can translocate to the nucleus and activate genes
that stimulate cell proliferation, such as cyclin D1 [51,52] and
c-Myc [53], whose promoters contain lymphoid enhancer
factor/T cell factor (LEF/TCF) transcription factor binding
sites [54]. Therefore, we predicted that compared with MUC1
non-expressing cells, cells expressing the MUC1 CT would
exhibit reduced levels of nuclear β-catenin, lower levels of
LEF-1 activity, and decreased expression of cyclin D1 and c-
Myc. To examine nuclear β-catenin levels in the presence or
absence of MUC1 expression, nuclear extracts of pcDNA-,
MUC1-, CD8/MUC1- ΔCT-, and CD8/MUC1-HEK293T cells
were prepared and equivalent protein aliquots were immuno-
blotted with β-catenin antibody. As shown in Fig. 5A, nuclear
β-catenin levels were drastically reduced in MUC1-HEK293T
and CD8/MUC1-HEK293T cells compared with pcDNA-
HEK293T and CD8/MUC1-ΔCT-HEK293T cells respectively.
Immunoblotting with antibody against lamin B1 confirmed
equal sample loading and transblot efficiencies of nuclear
proteins (Fig. 5B). Immunoblot analysis with antibody to the
cytoplasmic marker IκBα demonstrated lack of contamination
of the nuclear fractions with the cytoplasmic fractions (Fig. 5C).
3.4. The MUC1 CT blocks LEF-1-dependent transcription
Next, we compared LEF-1-dependent transcriptional activity
in MUC1 expressing and non-expressing cells using a LEF-1-
luciferase reporter plasmid. The LEF-1-luciferase construct
contains multimerized copies of an optimal LEF-1 binding site
motif cloned upstream of the firefly luciferase gene [55]. CD8/
MUC1- and CD8/MUC1-ΔCT-HEK293Tcells were transfected
with the LEF-1-luciferase plasmid, or the pGL2 luciferase only
Fig. 7. Expression of the MUC1 CT downregulates cyclin D1 and c-Myc expression. CD8/MUC1-ΔCT- and CD8/MUC1-HEK293T cells were analyzed by
immunofluorescence microscopy using antibodies to cyclin D1 (A, C) or c-Myc (B, D). (E, F) The nuclei of the cells in panels C and D respectively were
counterstained with DAPI. Final magnification of all images is ×200.
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transfection. As shown in Fig. 6A, CD8/MUC1-HEK293T cells
exhibited significantly reduced luciferase activity compared
with CD8/MUC1-ΔCT-HEK293T cells. Cotransfection of both
cells with β-catenin and LEF-1-luciferase plasmids led to
increased luciferase activity and no significant difference
between MUC1 expressing and non-expressing cells was
observed (Fig. 6B), thus demonstrating the β-catenin depen-
dence of LEF-1 transcriptional activity.
3.5. Expression of the MUC1 CT reduces cyclin D1 and c-Myc
levels
To determine the effect of MUC1 on cyclin D1 and c-Myc
expression, CD8/MUC1- and CD8/MUC1-ΔCT-HEK293T
cells were examined by immunofluorescence microscopy. InCD8/MUC1-HEK293T cells, cyclin D1 and c-Myc showed
weak and diffuse immunostaining distributed throughout the
cytoplasm and nucleus (Fig. 7A, B). In contrast, CD8/MUC1-
ΔCT-HEK293T cells exhibited profoundly increased staining
(Fig. 7C, D), localized primarily to the nucleus of the cells as
visualized by DAPI staining (Fig. 7E, F).
3.6. Expression of the MUC1 CT inhibits cell proliferation
Cyclin D1 and c-Myc are major effectors driving cells into
the proliferative phase of the cell cycle [56,57]. To determine if
MUC1 expression affected cell proliferation, equal numbers of
CD8/MUC1- and CD8/MUC1-ΔCT-HEK293T cells were
seeded in 24 well plates, cultured for 24, 48, 72, 96, or 120 h,
and viable cell numbers in the cultures were compared using the
XTT reagent (Fig. 8). Initially, we observed that there were no
Fig. 9. Muc1+/+ TSE cells exhibit decreased proliferation compared with Muc1−/
− cells. Muc1+/+ and Muc1−/− TSE cells were isolated and cultured at an ALI as
described in Materials and methods. At the indicated times, viable cell numbers
were quantified using the XTT reagent (circles, left y axis) and TER was
determined across the monolayers (triangles, right y axis). Each point represents
the mean±SD of triplicate cultures. *pb0.05 when comparing Muc1−/− with
Muc1+/+ cells.
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medium containing 10% FBS (Fig. 8A). However, when the
cells were cultured inmedium containing 3%FBS, CD8/MUC1-
ΔCT-HEK293T cells displayed significantly greater prolifera-
tion compared with CD8/MUC1-HEK293T cells (Fig. 8B). The
same result was seen with independently isolated clones of the 2
cells that expressed equal amounts of the transfected proteins
(Fig. 8C).
3.7. Primary TSE cells from Muc1+/+ mice show decreased cell
proliferation compared with Muc1−/− cells
We utilized a second cell culture system to assess the effect
of Muc1 expression on cell proliferation. Primary tracheal
epithelial cells were isolated from Muc1+/+ and Muc1−/− mice
(by convention, MUC1 is used for human andMuc for animals),
equal cell numbers were cultured at an air–liquid interface
(ALI), and cell proliferation was compared at various timeFig. 8. Expression of the MUC1 CT inhibits cell proliferation. CD8/MUC1-
ΔCT- and CD8/MUC1-HEK293T cells were cultured in DMEM containing
10% FBS (A) or 3% FBS (B, C) for the indicated times and viable cell numbers
quantified using the XTT reagent. Each bar represents the mean±SD of
triplicate cultures. *pb0.05 when comparing CD8/MUC1-ΔCT-HEK293T cells
with CD8/MUC1-HEK293T cells.points post-seeding. The ALI primary culture method provides
an in vitro system to analyze the growth characteristics of
airway epithelial cells in a manner that closely approximates
cell growth in vivo, as assessed by formation polarized epithelia
with high transepithelial electrical resistance (TER), differen-
tiation to ciliated and secretory cells, and physiologically
appropriate expression of key genes and ion channels [58]. We
observed that cultures of Muc1−/− cells contained significantly
greater cell numbers compared with Muc1+/+ cultures at days 3,
5, and 7 (Fig. 9). The fact that both cell types exhibited equal
numbers at day 1 indicated that the results were not simply due
to differences in the ability of the cells to adhere to the substrate.
Furthermore, by day 11 both cultures had reached the same cell
numbers indicating that the greater proliferation of Muc1−/−
cells was not due to decreased contact-mediated growth arrest.
As a confirmatory approach, measurement of TER during the
exponential growth phase revealed significantly greater TER in
Muc1−/− cultures compared with Muc1+/+ cells. We interpreted
the latter results as an indication that Muc1−/− cells had more
quickly formed a confluent monolayer with the establishment of
intercellular junctions compared with Muc1+/+ cells.
4. Discussion
The current results indicated that, similar to published studies
using breast and pancreatic cancer cells, MUC1 expressed by
non-malignant airway epithelial cells forms a coimmunopreci-
pitation complex with β-catenin. Moreover, when comparing
HEK293T cells transfected with CD8/MUC1 vs. CD8/MUC1-
ΔCT, we observed that cells expressing theMUC1CT displayed
decreased nuclear localization of β-catenin, reduced activation
of LEF-1, diminished expression of cyclin D1 and c-Myc, and
lowered cell proliferation. Decreased cell proliferation was also
observed in primary cultures of Muc1+/+ TSE cells compared
with Muc1−/− cells. Collectively, these results lead us to
conclude that MUC1 inhibits cell proliferation through a β-
catenin/LEF-1/cyclin D1/c-Myc pathway. We propose that this
effect is mediated, in large part, by recruitment of β-catenin to
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nuclear pool and reducing LEF/TCF transactivation of cyclin D1
and c-Myc. In support of this model, Stockinger et al. [59]
reported decreased β-catenin-dependent LEF-1 activity and
reduced cell proliferation following transfection of mammary
epithelial cells with E-cadherin. In the complementary approach,
Yang et al. [60] showed that decreased expression of E-cadherin
using an antisense oligonucleotide led to accumulation of β-
catenin in the nucleus, activation of the β-catenin/LEF/TCF
signaling pathway, and increased c-Myc expression.
We considered the possibility that our observations were not
physiologically relevant since they were obtained using
transfected cells overexpressing the full-length MUC1 or
CD8/MUC1 fusion proteins, that may have been processed
differently compared with endogenous MUC1. However,
several arguments against this possibility can be made. First,
MUC1 overexpression is a general phenotype of all tumor cells
[1], and the levels of MUC1 expression we obtained (and CD8/
MUC1 by implication) with transfected HEK293T cells was
generally equivalent to that normally seen in T47D, MCF7, and
MDA-MB468 breast cancer cell lines (unpublished observa-
tions). Second, although Kinlough et al. [61] reported that a
MUC1 mutant lacking the CQC dual Cys-palmitoylation sites
accumulated in endosomes, our prior study [34] clearly
demonstrated that the CD8/MUC1 fusion protein lacking the
CQC tripeptide was primarily expressed on the cell surface,
and not intracellularly. Third, phosphorylation of the MUC1
CT, both in the transfected full-length and CD8/MUC1 pro-
teins, is identical to that reported with endogenous MUC1
[8,30,42,44,46]. Fourth, the intracellular signaling pathway
activated in cells transfected with the full-length and CD8/
MUC1 constructs are the same as those in cells endogenously
expressing MUC1, particularly in the case of the Ras-Raf-
MEK-ERK cascade [18,28,34]. Finally, and most importantly,
our results that MUC1 expression was associated with
decreased cell proliferation has been independently reported
by other investigators [62].
The MUC1 CT contains a SAGNGGSSL sequence that
serves as the binding site for β-catenin [40]. This sequence fits a
canonical S(X)5SSL motif also present in E-cadherin and
adenomatous polyposis coli (APC), a cytoplasmic protein that
forms a multiprotein complex with β-catenin, axin, and
glycogen synthase kinase 3β (GSK3β) and promoting
proteosomal degradation of β-catenin. As originally reported
by Li et al. [41], GSK3β is involved in the degradation of
cytoplasmic β-catenin and the interaction between GSK3β and
MUC1 modulates MUC1's interaction with β-catenin. Further-
more, Huang et al. [63] used HEK293 cells transfected with β-
catenin, GSK3β, and the MUC1 CT to show that MUC1
transfection increased non-phosphorylated β-catenin and de-
creased phosphorylated β-catenin suggesting that it antago-
nized GSK3 β's targeting of β-catenin for degradation. It is
possible that different subclones of HEK293 used in our studies
and those of Huang et al. may be responsible for this apparent
discrepancy. E-cadherin also binds to γ-catenin and mapping
studies have shown that β- and γ-catenin harbor overlapping
binding sites on E-cadherin [54]. Binding of the two catenins toE-cadherin is mutually exclusive [31]. However, we were
unable to demonstrate a coimmunoprecipitation complex
between γ-catenin and the MUC1 CT, which supports previous
observations by Wen et al. [33], but is in conflict with those of
Yamamoto et al. [40]. Because the β- and γ-catenin binding
sites on E-cadherin are only partially overlapping, it is possible
that additional sequences outside of the S(X)5SSL motif, and
not present in MUC1, may contribute to γ-catenin binding.
Alternatively, since intracellular colocalization of MUC1 with
γ-catenin was detected in human breast carcinomas, but not in
normal mammary epithelium [64], this association may be
restricted to certain cell types.
Binding competition experiments have demonstrated that E-
cadherin, APC, and LEF bind to the same region of β-catenin
[65]. Moreover, Kondo et al. [66] reported that decreased
MUC1 expression led to increased E-cadherin-mediated cell–
cell adhesion, suggesting that MUC1 competes with E-cadherin
for binding to β-catenin. This prediction was confirmed in a
previous study using MUC1-transfected HEK293T and HeLa
cells [41]. Our current studies support those of Li et al. [41]
since, unlike mock-transfected cells, E-cadherin/β-catenin
coimmunoprecipitation was not seen in MUC1-HEK293T
cells. However, MUC1 expression did not inhibit binding of
γ-catenin to E-cadherin providing an independent result to
indicate lack of association between MUC1 and γ-catenin in
HEK293T cells.
An inverse relationship between intercellular adhesion
mediated by adherens junctions and β-catenin-dependent cell
proliferation has been known for some time. For example,
several laboratories have reported that activation or over-
expression of E-, VE-, or N-cadherin arrested cell growth, and
this effect relied on the presence of the cytoplasmic β-catenin
binding site in the different cadherins [59,67,68]. Conversely,
stimulation of cell proliferation (e.g. by FBS) was correlated
with loss of adherens junctions [69]. Thus, recruitment of β-
catenin to the plasma membrane by E-cadherin can decrease its
nuclear pool and antagonize LEF/TCF-dependent proliferative
signals. The studies reported here suggest that a similar effect
occurs following overexpression of MUC1. While the associ-
ation of MUC1 with decreased cell proliferation may appear
contradictory to its reported ability to act as an oncogene [64], a
review of the literature indicates that this field is controversial.
For example, while Tsutsumida et al. [70] showed that
inhibition of MUC1 expression by RNA interference lead to
decreased growth rate of the S2-013 pancreatic tumor cell line,
Hattrup and Gendler [63] reported that MUC1 knockdown in
BT-20 breast cancer cells resulted in increased proliferation.
Recognizing the conflicting data generated in different
laboratories, the latter authors cautioned against over-general-
ization of results from individual cell lines since, in the absence
of a detailed molecular mechanism, proliferation of different
cells may vary depending on factors such as cell type and
signaling context. In our study, we noted that the effect of
MUC1 expression on cell proliferation was only revealed at a
low serum concentration. Interestingly, Y46 in the CTof MUC1
is a site for epidermal growth factor receptor phosphorylation,
which enhances binding of β-catenin [30]. Although we have
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proliferation, the above-mentioned reports may be relevant in
this regard.
It is currently unclear which properties of MUC1 contribute to
the malignant phenotype in vivo. The finding that nuclear levels
of β-catenin were enhanced by overexpression of MUC1 in
pancreatic cell lines suggested that MUC1 may contribute to the
development of tumors by disruption of cadherin-mediated
intercellular adhesion [33]. In another study, however, over-
expression of MUC1 failed to alter the total levels of β-catenin or
its distribution among the cytoplasmic and nuclear fractions [41].
In addition, transfection of cancer cells withMUC1 led to nuclear
accumulation of its CT where it may stabilize β-catenin thereby
promoting transcriptional activation of cancer related genes
[32,33]. By contrast, the studies reported here indicated that
nuclear levels of β-catenin were decreased upon MUC1
overexpression in HEK293T cells (Fig. 5), and we were unable
to detect the MUC1 CT in the nucleus of these cells by
immunofluorescence microscopy (data not shown). Varying
levels of MUC1 and/or β-catenin in the different cell lines may
account for these disparate results as, for example, in the case of
MUC1/APC coimmunoprecipitation in ZR-75-1, but not other
breast cancer cells [71]. Our observations are more reminiscent of
those of Baldus et al. [72] who reported that MUC1 in primary
colorectal carcinomas was mostly present in a cytoplasmic or
membrane-associated immunohistochemical staining pattern,
whereas β-catenin additionally showed this pattern plus a nuclear
reactivity. In another immunohistologic study, Rahn et al. [73]
reported that the only instances of β-catenin codistribution with
MUC1 were with samples in which MUC1 staining appeared at
the cell membrane.
The ability of MUC1 to down-regulate cell proliferation
may have important physiological consequences at mucosal
surfaces, particularly with regard to the repair of damaged
epithelia. For example, following denudation of the airway
epithelium and exposure of the underlying basement mem-
brane, a coordinated and sequential series of cellular events
occur to reestablish normal epithelial barrier function. These
steps involve (a) detachment and dedifferentiation of epithelial
cells adjacent to the injured area, (b) cell migration and
proliferation to fill the injury, and (c) cell reattachment to the
basement membrane, redifferentiation, and growth arrest [74].
Several in vitro model systems have been developed to
investigate the cellular and molecular mechanisms controlling
these repair events [75,76]. Our own studies have utilized
hamster primary TSE cells grown on a collagen gel [9,10].
The results demonstrated that in early stage cultures, the cells
were proliferative, lacked intercellular contacts, and dediffer-
entiated, whereas in late stage cultures they had become non-
proliferative, restored cell–cell adhesion, and redifferentiated.
Thus, the changes in TSE cells that were observed in vitro
mirrored the sequential events of airway epithelial cell repair
in vivo. Moreover, an inverse relationship was observed
between hamster Muc1 expression and TSE cell proliferation,
i.e. Muc1 expression was low when the cells were
proliferative and high when the cells were not proliferating.
The data presented in the current report now provide amechanistic explanation for how MUC1/Muc1 expression
down-regulates cell proliferation through a β-catenin/LEF/
cyclin/c-Myc pathway. Ongoing studies are focused on further
exploring the role of MUC1 during airway epithelial repair.
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